DDrare: Database of Drug Development for Rare Diseases

84. サルコイドーシス
［臨床試験数：143，薬物数：221（DrugBank：79），標的遺伝子数：82，標的パスウェイ数：165］

Searched query = "Sarcoidosis"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = 1% lignocaine; 13NH3 PET/CT scan; 18F-FDG; 18F-FSPG; 18F-fluorodeoxyglucose; 18FDG PET/CT scan; 2% lignocaine; 68Ga-DOTANOC; 68Ga-DOTATATE; 68Ga-DOTATATE PET/CT; 99m technetium infliximab; 99mTc-Infliximab; ABPC; ACT-293987 / JNJ-67896049; ACTHAR Gel (adrenocorticotropic hormone); ACTHAR Gel 40 units twice weekly; ACTHAR Gel 80 units twice weekly.; ACZ885; AMPC; ARA 290; ATYR1923; ATYR1923 1.0 mg/kg; ATYR1923 3.0 mg/kg; ATYR1923 5.0 mg/kg; Abatacept; Acthar; Acthar Gel; Acthar gel; Adalimumab; Adrenocorticotropic hormone; All subjects will receive maraviroc 300mg orally twice a day for 6 weeks; Allogeneic stem cell transplantation; Ambrisentan; Anakinra; Analysis of gamma globulin; Antibiotic Regimen; Antituberculous therapy along with steroids; Armodafinil; Atorvastatin; Autologous hematopoietic stem cell transplantation; Azithromycin; Azithromycin 250Mg Capsule; Azithromycin monohydrate; BAL; Bardoxolone; Bardoxolone methyl; Blood sample; Bosentan; Bosentan monohydrate; C11-methionine; CC; CC-100004; CC-220; CC-220 0.3 mg Daily; CC-220 0.6mg Daily; CMK389; CNTO 148; CNTO1275; CNTO148; Calcium; Calcium Citrate with Vitamin D2; Calcium citrate; Canakinumab; Ciclesonide; Clarithromycin; Corticosteroid; Corticotropin; Cu-64 DOTATATE; Cyclophosphamide; Cysteine; D-methylphenidate; DELTACORTENE*10CPR 25MG; DEXAMETHASONE; DOTANOC; Dapsone; Device: Blood pressure; Device: Flexible bronchoscopy in moderate sedation; Device: Nested PCR for formalin-fixed tissues; Device: Nested PCR for fresh tissues; Device: Oxygen saturation; Device: Propofol dosage; Device: Real-time PCR for fresh tissues; Device: Recovery time after bronchoscopy; Dexamethasone; Dexamethasone 0,5mg; Diagnostic Test: 18F-FDG-PET/MRI; Diagnostic Test: 18F-GE180-PET/MRI; Diagnostic Test: 68Ga-DOTA-TOC PET/CT; Diagnostic Test: FDG-PET/CT with Rb82 Myocardial Perfusion Imaging; Diagnostic Test: Laboratory testing; Diagnostic Test: Spirometry; Diagnostic Test: simultaneous combined 18F-FDG PET and cardiac MRI imaging; Dotatate; Doxycycline; Ergocalciferol; Ethambutol; FDG; FLUORINE (18F) FLUDEOXYGLUCOSE; Fermented oyster extract; Fludeoxyglucose; Fluorodeoxyglucose; Folic acid; Formalin; Ga-68-DOTA-NOC; Gallium-68 DOTATATE; Gallium-68-DOTA-N-Octreotide; Genetic: RNA Sequencing; Glucocorticoid (prednisone or prednisolone); Gold; Golimumab; Golimumab Liquid in prefilled syringe; H.P. Acthar Gel; Habitrol; Heparin; Human anti TNF-alpha monoclonal antibody; Human anti-IL 12/23 monoclonal antibody; Humira; Hydroxychloroquine; Hydroxychloroquine + Prednisone; ILARIS; IMod.Fc, H-Fcv3-N4; Ilaris; Iloprost; Indium; Indium-111 Pentreotide; Infliximab; Influenza Vaccine; Inhaled Treprostinil; L-METHIONINE ([11C]METHYL); L-methionine; Levaquin; Levofloxacin; Lignocaine; Low dose prednisolone; METHOTREXATE; MTX; Maraviroc; Medium dose prednisolone; Methionine; Methotrexate; Methylphenidate; Methylphenidate (overencapsulated); Methylphenidate 10mg tablets; Methylprednisolone; Methylprednisolone bolus IV 15 mg/kg/d for 3 days.; Minomycin; Mycophenolate; N-acetyl-cysteine; Nelutri™; Nicotine; Nicotine patch; None; OCTREOTIDE; ORENCIA; Octreotide; Octreotide LAR / Sandostatin LAR (LAR=long acting release); Orencia; Other: 18F-FDG; Other: 18F-Fluorodeoxyglucose (18F-FDG) PET/CT; Other: Normal Saline for injection; Oxygen; Oyster; PD 0360324; PDA001 (cenplacel-L); PLAQUENIL*25CPR RIV 200MG; PREDNISONE; Pentoxifylline; Pirfenidone; Prednisolone; Prednison; Prednisone; Procedure: Bronchoalveolar lavage (BAL); Procedure: Bronchoscopy with bronchoalveolar lavage; Procedure: EBB + TBLB + BAL; Procedure: EBUS guided transbronchial forceps biopsy (EBUS-TBFB); Procedure: EBUS guided transbronchial needle aspiration (EBUS-TBNA); Procedure: EUS-FNA/EBUS-TBNA + BAL; Procedure: Endobronchial forceps biopsy; Procedure: Skin biopsy; Procedure: large bore (19G) histologic needle biopsy of the mediastinal lymph nodes; Procedure: venipunctures; Propofol; Quercetin; Radiation: Rubidium PET; Rapamune; Remicade; Repository Corticotropin Injection; Repository Corticotropin Injection -Treatment Extension; Rifampin; Rifampin and azithromycin.; Riociguat; Rituximab; Roflumilast; Rubidium; SELEXIPAG; SIROLIMUS; Sandostatin LAR; Sarilumab; Sarilumab 200 MG/1.14 ML Subcutaneous Solution [KEVZARA]_#1; Schisandra chinensis extract; Seasonal influenza vaccine available for the 2012-2013 vaccine campaign; Selexipag; Sirolimus; Sirolimus Ointment; THALIDOMIDE; Tadalafil; Thalidomide; Tofacitinib; Tofacitinib 5 mg twice daily; Tofacitinib 5mg Oral Tablet [Xeljanz] 16 week trial; Tofacitinib 5mg [Xeljanz] 1 year open-label extension; Tracleer; Tranilast; Treprostinil; Uptravi; Ursodeoxycholic Acid; Ursodeoxycholic acid; Ustekinumab; Ustekinumab liquid in prefilled syringe; Vitamin D2; Water

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	JPRN-UMIN000013831	2014/04/30	30/04/2014	Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation		Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.	inhaled ciclesonide (400maicrogram, twice daily, for three months)	Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan	NULL	Recruiting	20years-old	80years-old	Male and Female	40	Not selected	Japan

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

JPRN-UMIN000013831

2014/04/30

30/04/2014

Effect of inhaled corticosteroid therapy in pulmonary sarcoidosis patients who manifest airflow limitation

Pulmonary sarcoidosis patients who revealed airflow limitation in peak flow tests, increased respiratory resistance in IOS, or increased WA% in HRCT.

inhaled ciclesonide (400maicrogram, twice daily, for three months)

Department of Respirology, Graduate School of Medicine, Chiba University, Chiba, Japan

NULL

Recruiting

20years-old

80years-old

Male and Female

Not selected

Japan